POINT Biopharma Global Inc
NASDAQ:PNT
Intrinsic Value
POINT Biopharma Global, Inc. engages in the development and commercialization of rediopharmaceuticals for the treatment of cancer Its product candidates includes PNT2002 and PNT2003 for the treatment... [ Read More ]
The intrinsic value of one PNT stock under the Base Case scenario is 10.63 USD. Compared to the current market price of 12.5 USD, POINT Biopharma Global Inc is Overvalued by 15%.
Valuation Backtest
POINT Biopharma Global Inc
Run backtest to discover the historical profit from buying and selling PNT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
POINT Biopharma Global Inc
| Current Assets | 353.2m |
| Cash & Short-Term Investments | 339.2m |
| Receivables | 9.4m |
| Other Current Assets | 4.6m |
| Non-Current Assets | 124.5m |
| Long-Term Investments | 59.8m |
| PP&E | 59.5m |
| Other Non-Current Assets | 5.2m |
| Current Liabilities | 38.7m |
| Accounts Payable | 8.9m |
| Accrued Liabilities | 15.5m |
| Other Current Liabilities | 14.3m |
| Non-Current Liabilities | 14.8m |
| Long-Term Debt | 4.1m |
| Other Non-Current Liabilities | 10.7m |
Earnings Waterfall
POINT Biopharma Global Inc
|
Revenue
|
243.8m
USD
|
|
Operating Expenses
|
-136m
USD
|
|
Operating Income
|
107.8m
USD
|
|
Other Expenses
|
-11.2m
USD
|
|
Net Income
|
96.6m
USD
|
Free Cash Flow Analysis
POINT Biopharma Global Inc
PNT Profitability Score
Profitability Due Diligence
POINT Biopharma Global Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
POINT Biopharma Global Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
PNT Solvency Score
Solvency Due Diligence
POINT Biopharma Global Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Score
POINT Biopharma Global Inc's solvency score is 87/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PNT Price Targets Summary
POINT Biopharma Global Inc
According to Wall Street analysts, the average 1-year price target for PNT is 12.5 USD .
Ownership
PNT Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
PNT Price
POINT Biopharma Global Inc
| Average Annual Return | -20.1% |
| Standard Deviation of Annual Returns | 51.36% |
| Max Drawdown | -71% |
| Market Capitalization | 1.3B USD |
| Shares Outstanding | 106 569 000 |
| Percentage of Shares Shorted | 3.32% |
PNT News
Last Important Events
POINT Biopharma Global Inc
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
POINT Biopharma Global Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
POINT Biopharma Global, Inc. engages in the development and commercialization of rediopharmaceuticals for the treatment of cancer Its product candidates includes PNT2002 and PNT2003 for the treatment of prostate cancer and neuroendocrine tumors. The company is headquartered in Indianapolis, Indiana and currently employs 72 full-time employees. The company went IPO on 2020-07-10. The Company, through its subsidiaries is focused on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The firm's clinical-stage product candidates include PNT2003 and PNT2002 for the treatment of prostate cancer and neuroendocrine tumors. Its preclinical stage product candidates include Lu-PNT2004 and Lu-PNT2001. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2004 is a family of fibroblast activation protein-alpha (FAP-alpha), which targeted radioligands. PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors.
Contact
IPO
Employees
Officers
The intrinsic value of one PNT stock under the Base Case scenario is 10.63 USD.
Compared to the current market price of 12.5 USD, POINT Biopharma Global Inc is Overvalued by 15%.
You don't have any saved screeners yet
